NDAORALTABLET
Approved
Sep 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SOMA COMPOUND (aspirin; carisoprodol) by Viatris (2) is clinical pharmacology carisoprodol: carisoprodol is a centrally-acting muscle relaxant that does not directly relax tense skeletal muscles in man. First approved in 1960.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOMA COMPOUND is a fixed-dose oral combination of carisoprodol (centrally-acting muscle relaxant) and aspirin (nonsteroidal analgesic with anti-inflammatory properties) approved in 1960. It is indicated for acute musculoskeletal pain and muscle spasm relief through dual mechanism: carisoprodol depresses polysynaptic neurons in the spinal cord while aspirin inhibits prostaglandin biosynthesis. The combination provides both muscle relaxation and pain relief in a single tablet formulation.
LOE Approaching
Product is in LOE-approaching phase with moderate competitive pressure (30), suggesting contracting market presence and shrinking commercial team investment.
Mechanism of Action
CLINICAL PHARMACOLOGY Carisoprodol: Carisoprodol is a centrally-acting muscle relaxant that does not directly relax tense skeletal muscles in man. The mode of action of carisoprodol in relieving acute muscle spasm of local origin has not been clearly identified, but may be related to its sedative…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SOMA COMPOUND at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.